Exhibit 10.54

 

CONFIDENTIAL TREATMENT

 

THIRD AMENDMENT TO THE

COMMERCIAL SERVICES AGREEMENT

 

This Third Amendment to the Commercial Services Agreement (this “Third
Amendment”) is made this 30th day of September, 2009 (the “Amendment Effective
Date”), by and between ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited
partnership (“AstraZeneca”), and CUBIST PHARMACEUTICALS, INC., a Delaware
corporation (“Cubist”).

 

WHEREAS, AstraZeneca and Cubist previously entered into that certain Commercial
Services Agreement between AstraZeneca and Cubist, dated as of July 1, 2008 (as
amended as of February 26, 2009 and May 20, 2009, the “Agreement”); and

 

WHEREAS, AstraZeneca and Cubist desire to amend certain provisions of the
Agreement relating to the Promotion Plan and Annual Baseline Sales, as set forth
herein.

 

NOW THEREFORE, in consideration of the premises and the mutual covenants set
forth herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereby agree as
follows:

 

1.                                      PROMOTION PLAN.  THE AGREEMENT IS HEREBY
AMENDED SO THAT SECTION 3.1(B) IS DELETED IN ITS ENTIRETY AND REPLACED WITH THE
FOLLOWING:

 

“(B)         BY OCTOBER 16, 2009, FOR CALENDAR YEAR 2010, AND AT LEAST THREE
(3) MONTHS PRIOR TO THE COMMENCEMENT OF EACH CALENDAR YEAR THEREAFTER, THE
PARTIES SHALL UPDATE THE PROMOTION PLAN TO SPECIFY []* TO BE CONDUCTED BY CUBIST
WITH RESPECT TO THE CRITICAL CARE TARGET ACCOUNTS AND THE PEDIATRIC TARGET
ACCOUNTS FOR SUCH CALENDAR YEAR.  IN ADDITION TO THE FOREGOING ANNUAL UPDATES,
THE PARTIES MAY MODIFY THE PROMOTION PLAN FROM TIME TO TIME BY WRITTEN
AGREEMENT.”

 

2.                                      ANNUAL BASELINE SALES.  THE AGREEMENT IS
HEREBY AMENDED SO THAT SECTION 6.1(A) IS DELETED IN ITS ENTIRETY AND REPLACED
WITH THE FOLLOWING:

 

“(a)         Subject to modification pursuant to Section 6.1(b), the Annual
Baseline Sales for Calendar Year 2008 and 2009 and the baseline Gross Sales for
each Calendar Quarter (“Quarterly Baseline Sales”) in each such Calendar Year
are set forth in Exhibit A.  For each Calendar Year thereafter, the []*.”

 

3.                                      DEFINITIONS.  ALL TERMS USED, BUT NOT
DEFINED, IN THIS THIRD AMENDMENT SHALL HAVE THE RESPECTIVE MEANINGS SET FORTH IN
THE AGREEMENT.

 

4.                                      CONSTRUCTION.  THE PRINCIPLES SET FORTH
IN SECTION 1.2 OF THE AGREEMENT SHALL APPLY TO THIS THIRD AMENDMENT.

 

--------------------------------------------------------------------------------

*Confidential Treatment Requested.  Omitted portions filed with the Securities
and Exchange Commission (the “Commission”).

 

1

--------------------------------------------------------------------------------

 

5.                                      EFFECTIVE DATE; INCORPORATION OF TERMS;
CONTINUING EFFECT.  THIS THIRD AMENDMENT SHALL BE DEEMED EFFECTIVE FOR ALL
PURPOSES AS OF THE AMENDMENT EFFECTIVE DATE.  THE AMENDMENT SET FORTH IN THIS
THIRD AMENDMENT SHALL BE DEEMED TO BE INCORPORATED IN, AND MADE A PART OF, THE
AGREEMENT, AND THE AGREEMENT AND THIS THIRD AMENDMENT SHALL BE READ, TAKEN AND
CONSTRUED AS ONE AND THE SAME AGREEMENT (INCLUDING WITH RESPECT TO THE
PROVISIONS SET FORTH IN ARTICLE XVI (MISCELLANEOUS) OF THE AGREEMENT WHICH
SHALL, AS APPLICABLE, BE DEEMED TO APPLY TO THIS THIRD AMENDMENT (INCLUDING WITH
RESPECT TO THE GOVERNING LAW)).  EXCEPT AS OTHERWISE EXPRESSLY AMENDED BY THIS
THIRD AMENDMENT, THE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT IN
ACCORDANCE WITH ITS TERMS AND CONDITIONS.

 

6.                                      COUNTERPARTS.  THIS THIRD AMENDMENT MAY
BE EXECUTED SIMULTANEOUSLY IN TWO OR MORE COUNTERPARTS, EACH OF WHICH SHALL BE
DEEMED AN ORIGINAL, BUT ALL OF WHICH TOGETHER SHALL CONSTITUTE ONE AND THE SAME
INSTRUMENT.

 

[The remainder of this page has been intentionally left blank.]

 

--------------------------------------------------------------------------------

*Confidential Treatment Requested.  Omitted portions filed with the Commission.

 

2

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties, intending to be bound, have caused this Third
Amendment to be executed on their behalf by their duly authorized agent as of
the day and year first above written.

 

ASTRAZENECA PHARMACEUTICALS LP

 

CUBIST PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ Marion E. McCourt

 

By:

/s/ David W. J. McGirr

 

 

 

 

 

Name:

Marion E. McCourt

 

Name:

David W. J. McGirr

 

 

 

 

 

Title:

VP, Cornerstone

 

Title:

SVP, CFO

 

--------------------------------------------------------------------------------

*Confidential Treatment Requested.  Omitted portions filed with the Commission.

 

3

--------------------------------------------------------------------------------